Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 376,600 shares, a decrease of 16.1% from the October 15th total of 448,700 shares. Approximately 1.6% of the shares of the stock are sold short. Based on an average trading volume of 48,100 shares, the days-to-cover ratio is presently 7.8 days.

Institutional Trading of Gyre Therapeutics

A number of institutional investors have recently bought and sold shares of GYRE. Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics in the second quarter worth $218,000. Rhumbline Advisers bought a new stake in Gyre Therapeutics in the second quarter worth $123,000. WINTON GROUP Ltd bought a new stake in Gyre Therapeutics in the second quarter worth $220,000. Renaissance Technologies LLC bought a new stake in Gyre Therapeutics in the second quarter worth $166,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after buying an additional 90,557 shares during the last quarter. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Trading Down 5.2 %

NASDAQ GYRE opened at $13.12 on Monday. Gyre Therapeutics has a one year low of $8.26 and a one year high of $30.40. The stock has a 50 day moving average price of $13.83 and a 200-day moving average price of $12.98.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.